The new CMS doesn't reimburse for nosocomial infections. But the new rules can provide device and diagnostics companies with an opportunity to develop new products that help hospitals eliminate risk. For example, a release from TyRx announced the launch of an implantable cardiodefibrillator that is designed to inhibit surgical site infections. The AIGISRXâ„¢ ICD is an antibacterial coated mesh envelope developed to help stabilize the implanted device. It also contains the antimicrobial agents rifampin and minocycline. It provides antibiotic protection for about ten days after the procedure. It also helps to stabilize the device in the body. In the August 19, 2008 Federal Registry, CMS stated that "surgical site infection following certain cardiac device procedures is a strong HAC (hospital-acquired condition) candidate. The condition is high cost and high volume, triggers a higher-paying MS-DRG, and may be considered reasonably preventable through the application of evidence-based guidelines... we expect to propose surgical site infection following certain cardiac device procedures... as future candidate HACs."